Retatrutide vs Tirzepatide (Zepbound/Mounjaro): 2026 Comparison
Key takeaways
- Reta (~24-28%) beats tirzepatide (~21%) on weight loss in trials.
- Tirzepatide is approved and available now; reta is not.
- Reta adds a glucagon pathway that may raise energy expenditure.
- If you need a drug today, tirzepatide wins by default.
The core difference: two pathways vs three
Tirzepatide hits two receptors (GLP-1 and GIP). Retatrutide adds a third — glucagon — which is thought to raise resting energy expenditure on top of appetite suppression. That extra lever is the leading theory for why reta’s numbers run higher.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Class | Triple agonist (GLP-1/GIP/glucagon) | Dual agonist (GLP-1/GIP) |
| Brands | None yet (investigational) | Zepbound, Mounjaro |
| Avg weight loss | ~24–28% (TRIUMPH-1, 80 wk) | ~20.9% (SURMOUNT-1, 72 wk) |
| FDA status | Not approved; filing expected end 2026 | Approved and available |
| Available now? | No | Yes |
Which should you care about?
If you’re choosing a treatment today, the honest answer is tirzepatide — it’s approved, covered by some plans, and has years of real-world use. Retatrutide matters if you’re planning ahead or following the science. Either way, the nutrition playbook is identical: protect muscle with protein as appetite falls.
On a GLP-1 drug now or soon? Pre-portioned, high-protein meal delivery makes the protein target easy.
FAQ
Is retatrutide stronger than tirzepatide?
In the trial data, yes — retatrutide averaged roughly 24–28% weight loss vs tirzepatide’s ~21%. But these are separate trials, not head-to-head, and retatrutide is not approved yet.
Can I switch from Zepbound to retatrutide?
Not currently — retatrutide is investigational and not available by prescription. Realistic availability is late 2027 to 2028.
Do they have the same side effects?
Both are mostly gastrointestinal (nausea, etc.) during dose escalation. Retatrutide’s glucagon component can additionally raise heart rate slightly.
Why the third pathway matters
Both drugs quiet appetite through GLP-1 and GIP. Retatrutide adds glucagon-receptor agonism, and that single addition changes the math. Glucagon at these doses is thought to nudge resting energy expenditure upward and push the liver to burn stored fat, so reta works the calories-out side of the equation as well as calories-in. Tirzepatide leans almost entirely on eating less. That is the leading explanation for why reta’s trial numbers run several points higher despite a similar tolerability profile.
Side effects, compared
Day to day, the two feel similar: gastrointestinal complaints that cluster after each dose increase and settle at a stable dose. The one structural difference is reta’s glucagon component, which can modestly raise heart rate and shift glucose handling, so its trials titrate slowly and monitor closely. Tirzepatide has years of real-world safety data behind it; reta’s safety record is still being built in trials.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Main side effects | GI (nausea, diarrhea, vomiting, constipation) | GI (nausea, diarrhea, vomiting, constipation) |
| Extra consideration | Glucagon can raise heart rate slightly | Well-characterized, large real-world dataset |
| Tolerability lever | Slow dose escalation | Slow dose escalation |
Cost and access (when reta arrives)
Tirzepatide is here now, with some insurance coverage and manufacturer savings programs, though out-of-pocket cost without coverage remains high. Retatrutide has no price yet because it has no approval yet; launch pricing typically lands in the same ballpark as existing branded GLP-1 drugs, and coverage takes time to build after launch. If cost and availability matter today, tirzepatide is the practical choice.
Who each is best for
Choose what’s available (tirzepatide) if you want to start treatment now, value a long safety track record, or need insurance coverage. Watch retatrutide if you’re following the science, haven’t responded enough to current drugs, or are planning a few years out. Either way the eating plan is identical: hit your protein target so the weight you lose is fat, not muscle.
The Retatrutide 2026 series
The nutrition side most drug guides skip
We are a food site, so here is what the drug-only sites leave out: retatrutide and tirzepatide (Zepbound/Mounjaro) works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat – you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.
The four risks to manage (and the food fix)
| Nutrition risk | Why it happens | The food fix |
|---|---|---|
| Muscle & protein loss | Rapid weight loss plus too little protein – up to a third of lost weight can be lean muscle. | 1.2-1.6 g protein per kg body weight daily; anchor every meal and snack with protein. |
| Low micronutrients | Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium. | Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds, fortified foods. |
| Constipation | Slowed digestion plus less food and fiber. | Fiber-rich vegetables and fruit you can tolerate; steady fluids; move daily. |
| Dehydration & low energy | Reduced intake and GI fluid losses during dose changes. | Sip fluids and electrolytes through the day; never skip food entirely. |
What to actually eat on retatrutide and tirzepatide (Zepbound/Mounjaro)
- Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake. When you can only finish a few bites, make them protein.
- Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
- Easy formats for nausea days: protein smoothies (protein powder + fruit + spinach), broth-based soups, yogurt.
- Hydration and fiber: water and electrolytes through the day, plus tolerable high-fiber vegetables and fruit to keep things moving.
If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps – ask your prescribing clinician. The goal across the board: protect muscle and stay nourished while the medication does its job.
The simplest way to hit these numbers while your appetite is unpredictable is pre-portioned, macro-labeled meal delivery built for exactly this.
See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery
Sources & references
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine (2023).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022).
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Lilly press release (2026).
- Retatrutide – overview, mechanism, trial history. Wikipedia.
- Tirzepatide – overview. Wikipedia.
Related reading
Figures reflect Eli Lilly topline disclosures and peer-reviewed trial publications as of June 25, 2026. Retatrutide remains investigational; we will update on FDA action. Not medical advice.